News
LYEL
14.17
-4.77%
-0.71
Bank of America Securities Remains a Sell on Lyell Immunopharma (LYEL)
TipRanks · 1d ago
Weekly Report: what happened at LYEL last week (0803-0807)?
Weekly Report · 2d ago
Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock
Simply Wall St · 4d ago
Analysts’ Top Healthcare Picks: Lyell Immunopharma (LYEL), Janux Therapeutics Inc (JANX)
TipRanks · 6d ago
Lyell Immunopharma reports Q2 results
Seeking Alpha · 6d ago
Lyell Immunopharma reports Q2 net loss ($44.8M) vs. ($42.7M) last year
TipRanks · 6d ago
Press Release: Lyell Immunopharma Reports -3-
Dow Jones · 6d ago
Press Release: Lyell Immunopharma Reports -2-
Dow Jones · 6d ago
Press Release: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
Dow Jones · 6d ago
Lyell Immunopharma: Q2 Earnings Snapshot
Barchart · 6d ago
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Benzinga · 6d ago
Zillow downgraded, Global Payments upgraded: Wall Street’s top analyst calls
TipRanks · 6d ago
Lyell Immunopharma Price Target Announced at $36.00/Share by Stifel
Dow Jones · 6d ago
Lyell Immunopharma Initiated at Buy by Stifel
Dow Jones · 6d ago
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36
Benzinga · 6d ago
Lyell Immunopharma initiated with a Buy at Stifel
TipRanks · 08/05 20:36
Weekly Report: what happened at LYEL last week (0727-0731)?
Weekly Report · 08/03 09:22
Weekly Report: what happened at LYEL last week (0720-0724)?
Weekly Report · 07/27 09:23
Lyell Immunopharma Price Target Announced at $44.00/Share by B. Riley Securities
Dow Jones · 07/22 10:52
B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44
Benzinga · 07/22 10:42
More
Webull provides a variety of real-time LYEL stock news. You can receive the latest news about Lyell Immunopharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.